Myriad Genetics, Inc.
MYGN today announced new clinical data from a study with myRisk
Hereditary Cancer, a 25-gene hereditary cancer panel, that showed a 60 percent
increase in mutations detected in cancer predisposition genes in patients with
a prior history of colon cancer and/or polyps. Myriad is presenting this
clinical study and data from four other studies this week at the Collaborative
Group of the Americas on Inherited Colorectal Cancer (CGA) Annual Meeting in
Anaheim, Calif.
Patients with a family history of colon cancer also are vulnerable to other
cancers including breast, ovarian, endometrial and stomach cancer. The
detection of individuals with mutations associated with hereditary colon
cancer greatly increases the chances of successful medical management in those
at-risk individuals, which will save lives and reduce the downstream
healthcare costs. Also, once a patient has been identified as carrying a
deleterious mutation that patient's family members can be tested to determine
if they have an increased risk of cancer.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: News
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in